Hopital Foch Clinical Trials
Sponsors / Hopital Foch
According to ClinicalTrials.gov, Hopital Foch has served as lead sponsor on 200 registered trials. Across the portfolio, 13 are in recruitment, 3 are active non-recruiting, and 123 have reached completion. 45 trials have been terminated or withdrawn. The most common reasons cited for termination include slow or insufficient recruitment, business or strategic decisions. Across the portfolio, planned enrollment totals 41,023 participants. Data on this page mirrors the ClinicalTrials.gov registry as of the most recent refresh.
200
Total Trials
13
Recruiting
3
Other Active
123
Completed
45
Terminated / Withdrawn
41,023
Total Enrollment
Termination reasons: Other64% · Recruitment31% · Business2% · Funding2%
Recent Terminations
- Anesthesia"Discontinuation of DM production by the manufacturer leading to recruitment difficulties in the centers."
- Laryngeal Disease"Difficulty of recruiting and changing anesthesia methods"
- Polyps Uterus"change of practices"
- Lung Cancer, Non-small Cell"Evolution of the treatment procedures so that their is no more benefits for patients"
- Surgery"Logistical issues"
- Stroke"Difficulty in recruiting patients"
- Bladder Cancer"In the perioperative setting of radical cystectomy-bladder replacement no improvement of UTI was noticed in 10 patients who took Urell following the protocol"
- Cerebral Infarction"Medical practices have evolved and are not conform with the study procedure. Actually, all patients receive an ambulatory ECG telemetry monitoring"
- Pain"Budgetary and operational issues"
- Cardiac Surgery"Recruitment difficulties"
Active Trials (3 total)
- Adenomyosis PHASE2/PHASE3NCT04356664
- NCT07356752
- NCT04177511
- Glioblastoma, IDH-wildtype PHASE2NCT04945148
- NCT06537960
- NCT04615221
- Retinal Detachment PHASE3NCT06294847
- NCT04471168
- NCT05798286
- IgA Vasculitis PHASE3NCT05329090
- NCT03689842
- Xerostomia NANCT04222478
- Eschar NANCT06533436
- NCT04402242
- NCT05320263
- NCT04837339